Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA

Molecular Genetics and Metabolism

Volumn 93, Issue 4, 2008, Pages 411-418

  McIntyre, Chantelle ^a,b   Derrick Roberts, Ainslie Lauren ^b   Ranieri, Enzo ^a,b   Clements, Peter Roy ^a,b   Byers, Sharon ^a,b   Anson, Donald S ^a,b,c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Correction; HIV 1; Mice; MPS IIIA; Vector

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; DISACCHARIDE; HEPARAN SULFATE; LENTIVIRUS VECTOR; LYSOSOME ENZYME; SULPHAMIDASE; UNCLASSIFIED DRUG; URONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSDUCTION; HISTOCHEMISTRY; HISTOLOGY; LENTIVIRINAE; LIVER; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SANFILIPPO SYNDROME TYPE A; SINGLE DRUG DOSE; SOMATIC GENE THERAPY; SPLEEN; STORAGE DISEASE; VIRAL GENE THERAPY;

ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; BRAIN CHEMISTRY; DISACCHARIDES; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; HYDROLASES; LENTIVIRUS; LIVER; LYSOSOMES; MALE; MICE; MUCOPOLYSACCHARIDOSIS III; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPLEEN; TANDEM MASS SPECTROMETRY; URONIC ACIDS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS;

EID: 40849094270     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2007.11.008     Document Type: Article

References (28)

1. Neufeld E.F., and Muenzer J. The mucopolysaccharidoses. In: Scriver C.R., Beaudet A.L., Valle D., and Sly W.S. (Eds). The Metabolic and Molecular Bases of Inherited Disease. eightth ed. (2001), McGraw Hill, NY
2. Meikle P.J., Hopwood J.J., Clague A.E., and Carey W.F. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
3. Sly W.S., Vogler C., Grubb J.H., Levy B., Galvin N., Tan Y., Nishioka T., and Tomatsu S. Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc. Natl. Acad. Sci. USA 103 (2006) 15172-15177
4. Germain D.P. Enzyme replacement therapies for lysosomal storage disorders. Med. Sci. 21 (2005) 77-83
5. Shapiro E.G., Lockman L.A., Balthazor M., and Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis. 18 (1995) 413
6. Ponder K.P., and Haskins M.E. Gene therapy for mucopolysaccharidosis. Expert. Opin. Biol. Ther. 7 (2007) 1333-1345
7. Urayama A., Grubb J.H., Sly W.S., and Banks W.A. Developmentally regulated mannose 6-phosphate receptor mediated transport of a lysosomal enzyme across the blood brain barrier. Proc. Natl. Acad. Sci. USA 101 (2004) 12658-12663
8. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., and Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. USA 102 (2005) 14777-14782
9. Zheng Y., Ryazantsev S., Ohmi K., Zhao H.Z., Rozengurt N., Kohn D.B., and Neufeld E.F. Retrovirally transduced bone marrow has a therapeutic effect on brain in the mouse model of mucopolysaccharidosis IIIB. Mol. Genet. Metab. 82 (2004) 286-295
10. Fraldi A., Hemsley K., Crawley A., Lombardi A., Lau A., Sutherland L., Auricchio A., Ballabio A., and Hopwood J. Functional correction of CNS lesions in a MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum. Mol. Genet. 16 (2007) 2693-2702
11. Connolly J.B. Lentiviruses in gene therapy clinical research. Gene Ther. 9 (2002) 1730-1734
12. Anson D.S., McIntyre C., Thomas B., Koldej R., Ranieri E., Roberts A., Clements P., Dunning K., and Byers S. Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. Genet. Vaccines Ther. 5 (2007)
13. Bhaumik M., Muller V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., Wurzelmann S., Finamore P., Hopwood J.J., Walkley S.U., and Stanley P.A. A mouse model for mucopolysaccharidosis type IIIA (Sanfilippo syndrome). Glycobiology 9 (1999) 1389-1396
14. Hopwood J.J., and Elliott H. Diagnosis of Sanfilippo A syndrome by estimation of sulfamidase activity using a radiolabelled tetrasaccharide substrate. Clin. Chim. Acta 123 (1982) 241-250
15. Leaback D.H., and Walker P.G. Studies on glucosaminidase 4. The fluorimetric assay of N-acetyl-beta-glucosaminidase. Biochem. J. 78 (1961) 151-156
16. Blumenkrantz N., and Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal. Biochem. 54 (1973) 484-489
17. Fuller M., Rozaklis T., Ramsay S.L., Hopwood J.J., and Meikle P.J. Disease-specific markers for the mucopolysaccharidoses. Pediatr. Res. 56 (2004) 733-738
18. Sferra T.J., Backstrom K., Wang C., Rennard R., Miller M., and Hu Y. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol. Ther. 10 (2004) 478-491
19. Follenzi A., Sabatino G., Lombardo A., Boccaccino C., and Naldini L. Efficient delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13 (2002) 243-260
20. Pan D., Gunther R., Duan W., Wendell S., Kaemmerer W., Kafri T., Verma I.M., and Whitley C.B. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol. Ther. 6 (2002) 19-29
21. Fraldi A., Biffi A., Lombardi A., Visigalli I., Pepe S., Settembre C., Nusco E., Auricchio A., Naldini L., Ballabio A., and Cosma MP. SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochem. J. 403 (2007) 305-312
22. Mok H.P., Saved S., and Lever A. Stable gene expression occurs from a minority of integrated HIV-1 based vectors; transcriptional silencing is present in the majority. Gene Ther. 14 (2007) 741-751
23. Xu L., Mango R.L., Sands M.S., Haskins M.E., Ellinwood N.M., and Ponder K.P. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol. Ther. 6 (2002) 745-758
24. Di Natale P., Di Domentico C., Gargiulo N., Castaldo S., Gonzalez Y., Reyero E., Mithbaokar P., De Felice M., Follenzi A., Naldini L., and Villani R.D. Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector. Biochem. J. (2005) 639-646
25. Wang B., O'Malley T.M., Xu L., Vite C., Wang P., O'Donnell P.A., Ellinwood N.M., Haskins M.E., and Ponder K.P. Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol. Genet. Metab. 87 (2006) 8-21
26. Kobayashi H., Carbonaro D., Pepper K., Petersen D., Ge S., Jackson H., Shimanda H., Moats R., and Kohn D.B. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol. Ther. 11 (2005) 776-789
27. Daly T.M., Vogler C., Levy B., Haskins M.E., and Sands M.S. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. USA 96 (1999) 2296-2300
28. Stewart P.A., and Hayakawa E.M. Interendothelial junctional changes underlie the developmental "tightening" of the blood brain barrier. Devel. Brain Res. 32 (1987) 271-281